Celcuity, Inc. (CELC)
90.23
+1.99
(+2.26%)
USD |
NASDAQ |
Jun 11, 12:39
Celcuity Enterprise Value : 4.203B for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 4.203B |
| June 09, 2026 | 4.413B |
| June 08, 2026 | 4.163B |
| June 05, 2026 | 4.204B |
| June 04, 2026 | 4.407B |
| June 03, 2026 | 4.237B |
| June 02, 2026 | 4.356B |
| June 01, 2026 | 5.881B |
| May 29, 2026 | 6.361B |
| May 28, 2026 | 6.266B |
| May 27, 2026 | 6.470B |
| May 26, 2026 | 6.484B |
| May 22, 2026 | 6.677B |
| May 21, 2026 | 6.887B |
| May 20, 2026 | 6.780B |
| May 19, 2026 | 6.323B |
| May 18, 2026 | 6.382B |
| May 15, 2026 | 6.651B |
| May 14, 2026 | 6.506B |
| May 13, 2026 | 6.006B |
| May 12, 2026 | 6.017B |
| May 11, 2026 | 6.063B |
| May 08, 2026 | 6.328B |
| May 07, 2026 | 6.311B |
| May 06, 2026 | 6.678B |
| Date | Value |
|---|---|
| May 05, 2026 | 6.787B |
| May 04, 2026 | 6.946B |
| May 01, 2026 | 6.011B |
| April 30, 2026 | 5.803B |
| April 29, 2026 | 5.690B |
| April 28, 2026 | 5.741B |
| April 27, 2026 | 6.013B |
| April 24, 2026 | 5.788B |
| April 23, 2026 | 5.427B |
| April 22, 2026 | 5.855B |
| April 21, 2026 | 6.032B |
| April 20, 2026 | 5.742B |
| April 17, 2026 | 5.857B |
| April 16, 2026 | 5.992B |
| April 15, 2026 | 5.906B |
| April 14, 2026 | 5.779B |
| April 13, 2026 | 5.757B |
| April 10, 2026 | 5.600B |
| April 09, 2026 | 5.962B |
| April 08, 2026 | 5.590B |
| April 07, 2026 | 5.523B |
| April 06, 2026 | 5.459B |
| April 02, 2026 | 5.382B |
| April 01, 2026 | 5.396B |
| March 31, 2026 | 5.455B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Revolution Medicines, Inc. | 27.39B |
| Tango Therapeutics, Inc. | 3.788B |
| Kymera Therapeutics, Inc. | 5.859B |
| Cogent Biosciences, Inc. | 4.797B |
| Erasca, Inc. | 3.958B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -52.84M |
| Total Expenses (Quarterly) | 52.84M |
| EPS Diluted (Quarterly) | -0.9702 |
| Earnings Yield | -4.32% |
| Normalized Earnings Yield | -4.320 |